{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 56 of 92', 'CR845-CLIN3103', 'Measurements will be repeated if a value is out of the reference range due to a technical', 'issue, considered abnormal for the patient, or for other medical concerns. Only the', 'repeated measurement will be recorded.', 'In the event of a clinically significant change in blood pressure and/or heart rate, the', 'Investigator and dialysis staff will evaluate and manage the patient per standard dialysis', \"unit practices with knowledge of the patient's typical blood pressure and heart rate\", 'excursions.', 'Heart rate will be collected at each dialysis; if clinically significant and outside the', 'prespecified visits per schedule of events, the heart rate will be recorded on the relevant', 'CRF page.', '6.5.4.5', 'Electrocardiogram', 'The 12-lead ECGs will be obtained prior to the start of dialysis and will be read locally', 'by the Investigator or qualified designee. Electrocardiograms read by a qualified', 'designee must be endorsed by the Investigator. Clinically significant abnormalities or', 'worsening findings observed after the first dose of study drug will be reported as', 'treatment-emergent adverse events (TEAEs).', '6.5.4.6', 'Clinical Laboratory Tests', 'Blood samples for clinical laboratory tests including hematology, serum chemistry, and', 'serum pregnancy will be taken prior to dialysis and will be analyzed by a central', 'laboratory. The laboratory tests include the following:', 'Assessment', 'Parameters to be analysed', 'Serum Chemistry', 'Albumin, Alkaline Phosphatase, ALT/SGPT, AST/SGOT, Bilirubin', '(Total), BUN, Calcium, Chloride, Creatinine, Glucose, Phosphorus,', 'Potassium, Sodium', 'Hematology', 'Basophil %, Basophil (Absolute), Eosinophil %, Eosinophil', '(Absolute), Hematocrit, Hemoglobin, Lymphocyte %, Lymphocyte', '(Absolute), MCH, MCHC, MCV, Monocyte %, Monocyte', '(Absolute), Neutrophil %, Neutrophil (Absolute), Platelet, RDW,', 'Red Blood Cells, White Blood Cells', 'Serum Pregnancy (females of', 'Human chorionic gonadotropin (HCG)', 'childbearing potential only)', 'Processing and shipment of central laboratory samples will be described in the', 'Laboratory Manual.', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 57 of 92', 'CR845-CLIN3103', '6.5.4.7', 'Contraception and Pregnancy', 'All females of childbearing potential will have blood samples taken at Screening for', 'serum pregnancy testing. Females are considered to be of childbearing potential unless', 'they are:', 'Surgically sterile (ie, tubal ligation, bilateral oophorectomy, and/or', 'hysterectomy); or', 'Over 55 years of age and have not had a menstrual period in at least 1 year', 'Once they have consented to participate in the study, all women of childbearing potential', 'will be counseled on the importance of avoiding pregnancy and on the need to practice', 'adequate birth control for the duration of the study, from screening until 7 days after the', 'last dose of study drug.', 'Medically acceptable methods of birth control include hormonal contraceptives for at', 'least 1 cycle of treatment before study enrollment, an intrauterine device, and barrier with', 'spermicide.', 'Per inclusion criteria, male patients will agree not to donate sperm after the first dose of', 'study drug until 7 days after the last dose of study drug, and will agree to use a condom', 'with spermicide or abstain from heterosexual intercourse during the study until 7 days', 'after the last dose of study drug. No restrictions are required for a vasectomized male,', 'provided his vasectomy was performed >4 months prior to dosing. If sexual abstinence is', 'chosen by the patient, it must be the preferred and usual lifestyle of the patient and must', 'be practiced for the entire duration of the study.', 'Women will be counseled to contact the Investigator or his/her staff immediately if', 'pregnancy is suspected. Males will be instructed to report to the Investigator if their', 'partner becomes pregnant during the study.', 'If a patient becomes pregnant during the Double-blind Treatment Period or Open-label', 'Extension Phase or within 7-10 days after the last dose of study drug, the Investigator', 'will immediately discontinue the patient from the study and contact the Sponsor or', 'designee. Diligent efforts will be made to determine the outcome for all pregnancies in', 'the clinical study. Information on the status of the mother and the child will be', 'forwarded to the Sponsor. Generally, follow-up will occur within 6 to 8 weeks following', 'the estimated delivery date. Any premature termination of the pregnancy will be', 'reported. Both maternal and paternal exposure will be collected. For exposure involving', 'the female partner of a male patient, the necessary information must be collected from the', 'patient while respecting the confidentiality of the partner. A pregnancy report will be', 'completed.', '6.5.5', 'Additional Assessments', 'The following additional assessments will be collected during the Double-blind and', 'Open-label Extension Phases:', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}